# Phase 3 Pivotal Trial of NanoFlu™ in Older Adults

> **NCT04120194** · PHASE3 · COMPLETED · sponsor: **Novavax** · enrollment: 2654 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** NanoFlu
- **BIOLOGICAL:** Fluzone Quadrivalent

## Key facts

- **NCT ID:** NCT04120194
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-14
- **Primary completion:** 2020-10-29
- **Final completion:** 2020-12-13
- **Target enrollment:** 2654 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120194, "Phase 3 Pivotal Trial of NanoFlu™ in Older Adults". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04120194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*